Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 5 posts of 785 posts found.

Cerovive failure another blow for AstraZeneca

October 26, 2006
Research and Development, Sales and Marketing AstraZeneca, Cerovive, neuroscience

 A drug which had held out the promise of reducing the disabling effects of stroke on patients will be abandoned …

News

AstraZeneca abandons diabetes drug over safety concerns

May 5, 2006
Research and Development AstraZeneca, PPAR agonist

 AstraZeneca is to abandon its late-stage diabetes drug Galida after new results raised doubts about its safety.Galida is a PPAR …

News

AstraZeneca doubles trial size for stroke drug

December 13, 2005
Research and Development AstraZeneca, stroke

 Late stage clinical trials of AstraZeneca’s new stroke treatment have resumed after the company decided to double the number of …

News

R&D Scoreboard poor gauge of pharma investment in the UK

November 8, 2005
Research and Development AstraZeneca, GSK, Pfizer, R&D, R&D scoreboard

 The R&D Scoreboard is fundamentally flawed as a measure of R&D investment in the UK and pharmaceutical companies are continuing …

News

Faslodex launched in UK

May 19, 2004
AstraZeneca, Faslodex

The latest addition to AstraZeneca’s oncology franchise, breast cancer drug Faslodex has been launched in the UK.Licensed for the treatment …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026